The store will not work correctly when cookies are disabled.
3-(4-methoxyphenyl)-2-methyl-5-(4-nitrophenyl)-4H-pyrazolo[1,5-a]pyrimidin-7-one
ID: ALA4578790
PubChem CID: 2860157
Max Phase: Preclinical
Molecular Formula: C20H16N4O4
Molecular Weight: 376.37
Molecule Type: Unknown
Associated Items:
Names and Identifiers
Canonical SMILES: COc1ccc(-c2c(C)nn3c(=O)cc(-c4ccc([N+](=O)[O-])cc4)[nH]c23)cc1
Standard InChI: InChI=1S/C20H16N4O4/c1-12-19(14-5-9-16(28-2)10-6-14)20-21-17(11-18(25)23(20)22-12)13-3-7-15(8-4-13)24(26)27/h3-11,21H,1-2H3
Standard InChI Key: SZTQHKZVTLGFSD-UHFFFAOYSA-N
Molfile:
RDKit 2D
28 31 0 0 0 0 0 0 0 0999 V2000
5.0530 -16.8806 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.7693 -16.4740 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4819 -16.8806 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4819 -17.6990 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7693 -18.1177 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.0530 -17.6990 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2522 -17.9489 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.7900 -17.3022 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2793 -16.6403 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.9709 -17.3022 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.0402 -18.7405 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6197 -19.3204 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.4075 -20.1083 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6156 -20.3204 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.0385 -19.7465 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.2479 -18.9538 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.4036 -21.1121 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.9832 -21.6917 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.1896 -18.1106 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.1896 -18.9306 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.9002 -19.3360 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.6059 -18.9295 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.3137 -19.3370 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
10.0215 -18.9295 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
9.3137 -20.1561 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
8.6059 -18.1100 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.8976 -17.6992 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7693 -15.6512 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 1 0
1 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
1 9 1 0
8 10 1 0
11 7 1 0
12 11 2 0
13 12 1 0
14 13 2 0
15 14 1 0
16 15 2 0
11 16 1 0
14 17 1 0
17 18 1 0
19 4 1 0
19 20 1 0
21 20 2 0
21 22 1 0
22 23 1 0
23 24 1 0
23 25 2 0
26 22 2 0
27 26 1 0
27 19 2 0
2 28 2 0
M CHG 2 23 1 24 -1
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 376.37 | Molecular Weight (Monoisotopic): 376.1172 | AlogP: 3.58 | #Rotatable Bonds: 4 |
Polar Surface Area: 102.53 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 11.11 | CX Basic pKa: 0.34 | CX LogP: 2.96 | CX LogD: 2.96 |
Aromatic Rings: 4 | Heavy Atoms: 28 | QED Weighted: 0.43 | Np Likeness Score: -1.22 |
References
1. (2017) Arf6 inhibitors and methods of synthesis and use thereof, |